Low-Dose Interleukin-2 and Pembrolizumab for the Treatment of Stage IV Non-Small Cell Lung Cancer

NCT05493566 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

RECRUITING

Status

15

Enrollment

OTHER

Sponsor class

Conditions

Lung Non-Small Cell Carcinoma
Stage IV Lung Cancer AJCC v8
Stage IVA Lung Cancer AJCC v8
Stage IVB Lung Cancer AJCC v8

Interventions

BIOLOGICAL: Aldesleukin
BIOLOGICAL: Pembrolizumab

Sponsor

Emory University

Collaborators

[object Object]